Evidence map›Paper›PMID 21321062›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2011

Altered folate availability modifies the molecular environment of the human colorectum: implications for colorectal carcinogenesis.

Petr Protiva, Joel B Mason, Zhenhua Liu, Michael E Hopkins, Celeste Nelson, James R Marshall, Richard W Lambrecht, Swaroop Pendyala, Levy Kopelovich, Myungjin Kim and 4 more

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Genetic and epigenomic footprints of folate.Progress in molecular biology and translational science · 2012
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Petr ProtivaThe Rockefeller University, New York, New York, USA. petr.protiva@yale.edu
Joel B Mason
Zhenhua Liu
Michael E Hopkins
Celeste Nelson
James R Marshall
Richard W Lambrecht
Swaroop Pendyala
Levy Kopelovich
Myungjin Kim
Steven H Kleinstein
Peter W Laird
Martin Lipkin
Peter R Holt
Cornell University · USUConn Health · USUniversity of Southern California · USVA Connecticut Healthcare System · USNational Cancer Institute · USRockefeller University · USRoswell Park Comprehensive Cancer Center · USYale University · US

Funding

TRANSFORMING TRANSLATIONAL SCIENCE AND EDUCATION TO BENEFIT HUMAN HEALTHUL1RR024143 · NCRR · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2006 to 2011
$49.1M
Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI Mario Strazzabosco · 1986 to 2026
$31.1M
RETINOIDS AND EPITHELIAL DIFFERENTIATIONP30CA029502 · NCI · STRANG CANCER PREVENTION CENTER · PI RIVLIN, RICHARD S · 2002 to 2006
$4.1M
CpG Island Methylator Phenotype in Human Colorectal CancerR01CA118699 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LAIRD, PETER W · 2007 to 2011
$2.5M
One-carbon nutrients in cancer preventionK05CA100048 · NCI · TUFTS UNIVERSITY BOSTON · PI MASON, JOEL B · 2003 to 2007
$662k
ZINC AS A BIOLOGICAL RESPONSE MODIFIERP01CA029502 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LEVINE, BARBARA · 1985 to 2000
$360k
PHASE 1 CLINICAL PHARMACODYNAMIC STUDY OF FOLATE. WS n47 -261035111-261035111N01CN035111 · CN · HEALTH RESEARCH INC · PI MARSHALL, ERNEST · 2004 to 2006
–
NCI NIH HHS CA-29502-24NCI NIH HHS K05 CA100048NCI NIH HHS N01 CN035111NCI NIH HHS N01-CN35111NCI NIH HHS P01 CA029502NCI NIH HHS P30 CA029502NCI NIH HHS R01 CA118699NCRR NIH HHS 5UL1RR024143NCRR NIH HHS UL1 RR024143NIDDK NIH HHS P30 DK034989
6 · The paper itself

Abstract

Low folate status increases colorectal cancer risk. Paradoxically, overly abundant folate supplementation, which is not uncommon in the United States, may increase risk. The mechanisms of these effects are unknown. We conducted two translational studies to define molecular pathways in the human colon altered either by folate supplementation or by dietary folate depletion (followed by repletion). In the first study, 10 healthy, at-risk volunteers (with documented stable/normal folate intake) received supplemental folic acid (1 mg/d) for 8 weeks. In the second study, 10 similar subjects were admitted to a hospital as inpatients for 12 weeks to study folate depletion induced by a low folate diet. A repletion regimen of folic acid (1 mg/d) was provided for the last 4 of these weeks. Both studies included an 8-week run-in period to ensure stabilized folate levels prior to intervention. We obtained 12 rectosigmoid biopsies (from 4 quadrants of normal-appearing mucosa 10-15 cm from the anal verge) at baseline and at measured intervals in both studies for assessing the primary endpoints: genome-wide gene expression, genomic DNA methylation, promoter methylation (depletion/repletion study only), and p53 DNA strand breaks. Serum and rectosigmoid folate concentrations accurately tracked all changes in folate delivery (P < 0.05). In the first study, gene array analysis revealed that supplementation upregulated multiple inflammation- and immune-related pathways in addition to altering several 1-carbon-related enzymes (P < 0.001). In the second study, folate depletion downregulated genes involved in immune response, inflammation, the cell cycle, and mitochondrial/energy pathways; repletion reversed most of these changes. However, changes in gene expression after repletion in the second study (involving immune response and inflammation) did not reach the levels seen after supplementation in the first study. Neither genomic nor promoter-specific DNA methylation changed during the course of the depletion/repletion protocol, and genomic methylation did not change with supplementation in the first study. p53 DNA strand breaks increased with depletion after 12 weeks. In sum, depletion downregulates, whereas repletion or supplementation upregulates pathways related to inflammation and immune response. These findings provide novel support to the concept that excessive folate supplementation might promote colorectal carcinogenesis by enhancing proinflammatory and immune response pathways. These results indicate that modest changes in folate delivery create substantial changes in the molecular milieu of the human colon.

Indexed as

AdultAgedBiological AvailabilityCell Transformation, NeoplasticColonColorectal NeoplasmsDietary SupplementsDNA BreaksDNA MethylationFemaleFolic AcidFolic Acid DeficiencyGene ExpressionGene Expression ProfilingHumansMaleFolic AcidTumor Suppressor Protein p53

Identifiers

PMID21321062
PMCPMC3742550
OpenAlexW2144849875

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.